🎉 M&A multiples are live!
Check it out!

Karyopharm Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Karyopharm Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Karyopharm Therapeutics Overview

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.


Founded

2008

HQ

United States of America
Employees

279

Website

karyopharm.com

Financials

LTM Revenue $146M

LTM EBITDA n/a

EV

$121M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Karyopharm Therapeutics Financials

Karyopharm Therapeutics has a last 12-month revenue of $146M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Karyopharm Therapeutics achieved revenue of $145M and an EBITDA of -$38.6M.

Karyopharm Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Karyopharm Therapeutics valuation multiples based on analyst estimates

Karyopharm Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $146M $145M XXX XXX XXX
Gross Profit $152M $141M XXX XXX XXX
Gross Margin 104% 97% XXX XXX XXX
EBITDA -$118M -$38.6M XXX XXX XXX
EBITDA Margin -81% -27% XXX XXX XXX
Net Profit -$165M -$143M XXX XXX XXX
Net Margin -113% -99% XXX XXX XXX
Net Debt $34.9M $119M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Karyopharm Therapeutics Stock Performance

As of April 15, 2025, Karyopharm Therapeutics's stock price is $4.

Karyopharm Therapeutics has current market cap of $35.4M, and EV of $121M.

See Karyopharm Therapeutics trading valuation data

Karyopharm Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$121M $35.4M XXX XXX XXX XXX $-14.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Karyopharm Therapeutics Valuation Multiples

As of April 15, 2025, Karyopharm Therapeutics has market cap of $35.4M and EV of $121M.

Karyopharm Therapeutics's trades at 0.8x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Karyopharm Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Karyopharm Therapeutics and 10K+ public comps

Karyopharm Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $121M XXX XXX XXX
EV/Revenue 0.8x XXX XXX XXX
EV/EBITDA -3.1x XXX XXX XXX
P/E -0.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Karyopharm Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Karyopharm Therapeutics Valuation Multiples

Karyopharm Therapeutics's NTM/LTM revenue growth is 7%

Karyopharm Therapeutics's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Karyopharm Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Karyopharm Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Karyopharm Therapeutics and other 10K+ public comps

Karyopharm Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -1% XXX XXX XXX XXX
EBITDA Margin -27% XXX XXX XXX XXX
EBITDA Growth -67% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -20% XXX XXX XXX XXX
Revenue per Employee $0.5M XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 79% XXX XXX XXX XXX
R&D Expenses to Revenue 99% XXX XXX XXX XXX
Opex to Revenue 178% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Karyopharm Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Karyopharm Therapeutics M&A and Investment Activity

Karyopharm Therapeutics acquired  XXX companies to date.

Last acquisition by Karyopharm Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Karyopharm Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Karyopharm Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Karyopharm Therapeutics

When was Karyopharm Therapeutics founded? Karyopharm Therapeutics was founded in 2008.
Where is Karyopharm Therapeutics headquartered? Karyopharm Therapeutics is headquartered in United States of America.
How many employees does Karyopharm Therapeutics have? As of today, Karyopharm Therapeutics has 279 employees.
Who is the CEO of Karyopharm Therapeutics? Karyopharm Therapeutics's CEO is Mr. Richard Paulson, M.B.A..
Is Karyopharm Therapeutics publicy listed? Yes, Karyopharm Therapeutics is a public company listed on NAS.
What is the stock symbol of Karyopharm Therapeutics? Karyopharm Therapeutics trades under KPTI ticker.
When did Karyopharm Therapeutics go public? Karyopharm Therapeutics went public in 2013.
Who are competitors of Karyopharm Therapeutics? Similar companies to Karyopharm Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Karyopharm Therapeutics? Karyopharm Therapeutics's current market cap is $35.4M
What is the current revenue of Karyopharm Therapeutics? Karyopharm Therapeutics's last 12-month revenue is $146M.
What is the current EV/Revenue multiple of Karyopharm Therapeutics? Current revenue multiple of Karyopharm Therapeutics is 0.8x.
What is the current revenue growth of Karyopharm Therapeutics? Karyopharm Therapeutics revenue growth between 2023 and 2024 was -1%.
Is Karyopharm Therapeutics profitable? Yes, Karyopharm Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.